June 9, 2026 · The Annals of thoracic surgery · DOI: 10.1016/j.athoracsur.2026.05.037

STAGE II NON-SMALL CELL LUNG CANCER: UPFRONT SURGERY OR NEOADJUVANT CHEMOIMMUNOTHERAPY

Listen to this summary

The authors investigate whether neoadjuvant chemoimmunotherapy offers better overall survival compared to upfront surgery in stage-II non-small cell lung cancer patients. Their analysis reveals that while neoadjuvant chemoimmunotherapy improves survival compared to surgery in the 8th edition TNM database, results are similar in the 9th edition. Additionally, chemoimmunotherapy shows superior pathological response rates and event-free survival compared to chemotherapy, although surgical outcomes remain comparable.

Riccardo Tajè, Filippo Tommaso Gallina, Jonathan David Spicer

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play